There are dozens of GLP-1 medicines in clinical development, seeking to improve efficacy, tolerability and differentiate #weightloss #MASH An update on the GCGR-GLP-1R agonist Pemvidutide was provided by Altimmune, Inc. March 13 ir.altimmune.com/static-files/2…

🚨 TIRZ & SEMA: Cost-Effectiveness 🚨 💊 Powerful for wt loss & cutting diabetes/heart dz risk, but not cost-effective at current net prices. 💰 To be a "good value," prices must drop 30%+ (TIRZ) & 80%+ (SEMA). 📉 Bottom Line: Should insurers cover them? ow.ly/7j3E50ViL1j

The interest in exploring therapeutic roles for GLP-1RAs in rare conditions continues with a report on a single individual with generalized lipodystrophy on oral semaglutide enabling discontinuation of high dose #insulin therapy #insulin resistance diabetesjournals.org/care/article/d…

In studies of metabolically healthy/unhealthy #obesity APOC3 was identified as a novel predictor for obesity stratification medrxiv.org/content/10.110…

A look at the effect of weight regain vs. maintenance after bariatric surgery on health outcomes. Signals pointing towards the clinical need for combination therapies in some patients to reduce risk of MACE (pharmacotherapy post-surgery) thelancet.com/journals/lanep…

The SOUL CVOT with oral semaglutide #T2D 14% reduction in MACE. The mean follow-up was 47.5 months; NNT over 3 yrs=50; 2.95 kg placebo-subtracted #weightloss 26.9% baseline use of SGLT2i #CVD #ACC2025 nejm.org/doi/full/10.10…

Lepodisiran cuts lp(a) by 94% These are incredible times. These technologies have the potential to annihilate a major heart disease risk factor investor.lilly.com/news-releases/…

Phase 1 MAD 6 week data for the once weekly GUBRA investigational amylin analogue GUBamy with a t1/2 of ~11 days #weightloss #obesity AbbVie investors.gubra.dk/news-and-annou…

Science literacy is collapsing. And with it, the foundations of civilization. People fear vaccines more than viruses. So diseases we once defeated are coming back. They fear GMOs more than hunger. So we reject tools that could feed millions. They fear nuclear more than climate

Very cool to see Daniel J Drucker speak about a patient w/profound improvements in their PsA with a single injection of TZP. Similar to an experience w/a patient I shared previously. Congrats on the Warren Triennial Prize Dr Drucker

The expanding universe of GLP-1 medicines-with dozens of new molecular entities in the clinic, how will they differentiate beyond #weightloss #obesity #diabetes #heartdiseasen Nature Reviews Drug Discovery nature.com/articles/s4157…

🙌Outstanding 🙏🏻Thanks to the Lean Mass HyperResponder study published in JACC: Advances, we now have a modern, real-world confirmation of what decades of science have consistently proven: High LDLc causes atherosclerosis. 🫀📈 No matter how “metabolically healthy” you are,

Obesity is unique: the disease narrative has been driven in part by corporations with commercial interests. That once filled a void — there was very little advocacy. But the field is maturing. It’s time for public institutions & independent, patient-centered voices to lead

I was discussing Casey Mean’s dangerous grift a year ago (and Huberman’s for even longer): ⬇️⬇️⬇️

Its 4 months since the Lancet Commission on Obesity was published. Do you think it moved the needle in a meaningful way?

Honored to be an author-alongside so many prestigious coauthors-on this important work tackling obesity in primary care. sciencedirect.com/science/articl…

A pilot study using PET-MRI to visualize carotid artery inflammation in PPL with #T2D treated with semaglutide over 26 weeks sciencedirect.com/science/articl… #Atherosclerosis

AGI 2027, my eye. Folks, we have seen this movie before. Don’t get taken a second time. In 2012 Google's cofounder Sergey Brin promised that self-driving cars would be available for everyone within five years. Unless you live in SF, Phoenix, LA, or a handful of other cities,

One was good, 2 and 3 appear better here first-in-class, unprecedented tetra-agonists with high potency at GLP-1R, GIPR, GcgR, and Y2R with biased agonism pubs.acs.org/doi/10.1021/ja… #obesity #weightloss

Camurus and Lilly enter collaboration for long-acting FluidCrystal® incretins #Weightloss Selected from dual GIP and GLP-1 receptor agonists, triple GIP, glucagon and GLP-1 receptor agonists, and an option to include amylin receptor agonists. camurus.com/media/press-re…